Study S002782

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase Ib/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GZR18 Injection in Chinese Obese/Overweight Patients

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT06256536
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1; PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 60
Start: 2022-07-14
Primary completion: 2023-10-22
Lead sponsor: Gan and Lee Pharmaceuticals, USA
Conditions: Obesity; Overweight
Interventions: DRUG:GZR18; OTHER:Placebo
Results posted: FALSE

Registered primary outcomes

Incidence of adverse events and serious adverse events [38 weeks]
Changes in weight from baseline to the end of treatment [35 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0002818	GZR18, a GLP-1 analog with once-weekly or bi-weekly dosing for body weight management: A randomized, placebo-controlled, phase 1b/2a trial. Ji L, Cell reports. Medicine	2026	Randomized trial	PMID 41956096 DOI	cites ClinicalTrials.gov:NCT06256536; registry reference DERIVED:41956096